- to be eligible to enroll in the study, subjects must not: - require ventilatory support at the time of enrollment. - concurrent pulmonary bacterial infection - taking light sensitive medications - have lupus diagnosis - enrolled in an existing covid-19 trial - taking in-patient vitamin oral supplementation - severe mental or medical disability - history of melanoma or dysplastic nevus syndrome - prisoner - active tuberculosis or cystic fibrosis, severe chronic obstructive pulmonary disease (copd) or pulmonary fibrosis requiring home supplemental oxygen - pre-existing pulmonary hypertension - inr > 2, lft 6 times greater than baseline - stage 3b ckd or esrd diagnosis before covid-19 onset - evidence of cirrhosis - evidence of pre-existing vascular disorder or coagulopathy - irreversible bleeding disorder - patients who are not full code - taking oral light sensitizing medications (see appendix) or using light sensitizing topical - medication in the phototherapy treatment zones - taking in patient or at home vitamin d supplementation - have any photosensitive skin disorder such as systemic lupus erythematosus, porphyria or - pseudoporphyria, polymorphous light eruption xeroderma pigmentosa, chronic actinic - dermatitis, hydroa vacciniforme, dermatomyositis bloom syndrome, rothmund thomas - syndrome, cockayne syndrome - requiring oxygen supplementation via cpap/bipap, ventilator support, high flow nasal - prong therapy (hfnp) - concurrent pulmonary bacterial infection at the time of enrollment - previous hospital admission for covid-19 symptoms

- to be eligible to enroll in the study, subjects must not: - require ventilatory support at the time of enrollment. - concurrent pulmonary bacterial infection - taking light sensitive medications - have lupus diagnosis - enrolled in an existing covid-19 trial - taking in-patient vitamin oral supplementation - severe mental or medical disability - history of melanoma or dysplastic nevus syndrome - prisoner - active tuberculosis or cystic fibrosis, severe chronic obstructive pulmonary disease (copd) or pulmonary fibrosis requiring home supplemental oxygen - pre-existing pulmonary hypertension - inr > 2, lft 6 times greater than baseline - stage 3b ckd or esrd diagnosis before covid-19 onset - evidence of cirrhosis - evidence of pre-existing vascular disorder or coagulopathy - irreversible bleeding disorder - patients who are not full code - taking oral light sensitizing medications (see appendix) or using light sensitizing topical - medication in the phototherapy treatment zones - taking in patient or at home vitamin d supplementation - have any photosensitive skin disorder such as systemic lupus erythematosus, porphyria or - pseudoporphyria, polymorphous light eruption xeroderma pigmentosa, chronic actinic - dermatitis, hydroa vacciniforme, dermatomyositis bloom syndrome, rothmund thomas - syndrome, cockayne syndrome - requiring oxygen supplementation via cpap/bipap, ventilator support, high flow nasal - prong therapy (hfnp) - concurrent pulmonary bacterial infection at the time of enrollment - previous hospital admission for covid-19 symptoms